Company Filing History:
Years Active: 2018-2021
Title: The Innovations of Benjamin Kebble
Introduction
Benjamin Kebble is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of humanized monoclonal antibodies. With a total of two patents to his name, Kebble's work is recognized for its potential impact on medical treatments.
Latest Patents
Kebble's latest patents include the Anti-αβTCR antibody. This invention relates to humanized monoclonal antibodies that comprise the CDRs of murine antibody BMA031. These antibodies bind to the apTCR.CD3 complex and possess improved biological properties. This innovation showcases Kebble's commitment to advancing therapeutic options in immunology.
Career Highlights
Benjamin Kebble is currently associated with Genzyme Corporation, a leading biotechnology company. His work at Genzyme has allowed him to focus on groundbreaking research and development in the field of monoclonal antibodies. His contributions have been instrumental in pushing the boundaries of what is possible in medical science.
Collaborations
Kebble has collaborated with notable colleagues such as Daniel Snell and Andreas Menrad. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their shared field of expertise.
Conclusion
In summary, Benjamin Kebble is a distinguished inventor whose work in humanized monoclonal antibodies has the potential to revolutionize medical treatments. His patents and collaborations reflect his dedication to innovation in biotechnology.